针对BRAF V600E阳性胰腺腺癌的向治疗:两个病例报告
Shivani Shah1, Tabeer Rana2, Pragnan Kancharla3
1Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA, U.S.A.; shivani.shah@ahn.org.
Cancer genomics & proteomics
|July 3, 2023
概括
用达布拉芬尼和特拉美丁尼的向治疗对BRAF V600E突变胰腺癌显示出有前途. 早期下一代测序对于识别这些罕见突变和指导胰腺管道腺癌的治疗决策至关重要.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 胰腺管腺癌 (PDAC) 的预后不佳,转移性疾病的治疗选择有限.
- 在PDAC中,BRAF突变是罕见的 (大约. 3%),对BRAF突变的PDAC的研究很少.
- 下一代测序 (NGS) 能够识别像BRAF.这样的可向突变.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K